|Trade names||Befol (RU)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||282.77 g/mol g·mol−1|
|3D model (JSmol)|
Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol). It is a non-competitive reversible inhibitor of monoamine oxidase A that exhibits selective action on serotonin deamination. Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|